Effect of Tamsulosin in Preventing Ureteral Stent-Related Morbidity: A Prospective Study

Damiano, Rocco; Autorino, Riccardo; Sio, Marco De; Giacobbe, Alessandro; Palumbo, I.M.; D’Armiento, Massimo

doi:10.1089/end.2007.0257

Cited by 94 publications

(47 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Damiano et al 15 and Wang et al 8 have shown tamsulosin to be an efficacious therapy for stent-related symptoms. Usual care medication administration was used in our study and we found 65% of patients in the placebo group and 55% of patients in the lidocaine group were on tamsulosin.…”

Section: Discussionmentioning

confidence: 99%

Intraureteral lidocaine for ureteral stent symptoms post-ureteroscopy: A randomized, phase 2, placebo-controlled trial

Roberts¹,

Leslie

Robb

et al. 2017

CUAJ

View full text Add to dashboard Cite

Introduction: Ureteral stent and ureteral manipulation-related pain is a significant complication for patients undergoing ureteroscopy. Herein, we report a phase 2, randomized trial to assess efficacy of direct instillation of intraureteral lidocaine in reducing postoperative pain and ureteral stent symptoms. Methods: We performed a randomized, double-blinded trial of patients undergoing elective ureteroscopy for ureteral calculi. Patients were randomized to direct instillation of 2% lidocaine plus bicarbonate, or to normal saline as control. The primary outcome of interest was early postoperative pain scores. Patients completed10-point visual analog pain scale at one-hour, two-hour, four-hour, 24-hours, four-and seven-day time points. Other outcome measurements collected included a medication diary and voiding questionnaire. Results: A total of 41 patients were randomized in the study. Mean flank pain scores at one hour were 2.2 (±2.9) vs.1.9 (±2.4) in the intervention and placebo group, respectively (p=0.84). There was no significant difference at any time point between the intervention and placebo groups in patient-reported pain scores. Patients reported lower dysuria scores at all time points in the lidocaine group, however, none reached statistical significance. There was no difference in complication rates or adverse effects between groups. Conclusions: In this randomized, phase 2 study, direct instillation of lidocaine into the ureter did not appear to significantly improve pain or voiding symptoms following stented ureteroscopy.

show abstract

Section: Discussionmentioning

confidence: 99%

Intraureteral lidocaine for ureteral stent symptoms post-ureteroscopy: A randomized, phase 2, placebo-controlled trial

Roberts¹,

Leslie

Robb

et al. 2017

CUAJ

View full text Add to dashboard Cite

show abstract

“…Then another two studies elucidating the efficacy of alfuzosin and tamsulosin on stent symptoms were performed by Buddingfield et al and Damino et al, respectively (5, 6). Meta-analyses also showed that α-blockers are associated with improvements in stent symptoms (16, 17).…”

Section: Discussionmentioning

confidence: 99%

“…The results in the second two weeks with the stent in situ further indicated the efficacy of Doxazosin Oral Intake Therapy on stent symptoms, which were less dependent on patient surgical complications, preoperative condition and postoperative recovery. The outcomes obtained at 4 weeks after stent withdrawal were proposed to be the baseline data without the impact of ureteral calculi and related hydronephrosis (6). However, we still noted a trend for higher abdominal pain in the placebo group after stent removal; this finding might demonstrate the residual effects of the treatment or the prevalence of symptoms in background population (3).…”

Section: Discussionmentioning

confidence: 99%

“…To assess urinary symptoms and pain associated with ureteral stent, patients were asked to complete the brief-form Chinese version USSQ 2 weeks and 4 weeks after stent placement and 4 weeks after stent withdrawal (11). The outcomes obtained at 4 weeks after stent withdrawal were proposed to be the baseline data without the impact of ureteral stone and related hydronephrosis (6). Patients received a prescription for diclofenac sodium 50mg×10 suppositories.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Doxazosin oral intake therapy to relieve stent - related urinary symptoms and pain: a prospective, randomized, controlled study

Zhang

Pan

et al. 2016

Int. braz j urol.

View full text Add to dashboard Cite

Objective:To assess the impact of Doxazosin Oral Intake Therapy on urinary symptoms and pain in patients with indwelling ureteral stentsPatients and Methods:A total of 239 patients with ureteral stone-related hydronephrosis who underwent a double-J stent insertion after ureteroscopic lithotripsy were enrolled. Patients were randomized to receive doxazosin cotrolled release 4 mg once daily for 4 weeks or matching placebo. Patients completed the brief-form Chinese version Ureteric Stent Symptom Questionnaire (USSQ) and quality of life (QoL) score 2 weeks and 4 weeks after stent placement and 4 weeks after stent withdrawal. The analgesic use was also recorded during the stenting period.Results:Patients in Doxazosin Oral Intake Therapy group, in the first 2 weeks and second 2 weeks with the stent in situ, expressed significant lower daytime frequency (p=0.028 and p=0.038), nocturia (p=0.021 and p=0.008) and urgency (p=0.012 and p=0.014), respectively. Similarly, flank pain score, QoL score and analgesic use were also significant less in the stenting period. There was no significant difference in scores of urinary symptoms, pain and QoL during the post-stent period between two cohorts.Conclusions:Doxazosin Oral Intake Therapy reduced stent-related urinary symptoms, pain and the negative impact on QoL.

show abstract

“…In two trials using oral alfuzosin, there was a statistically significant positive impact on urinary symptoms, pain, physical activity, and sleep [17,18]. In two additional studies reporting the use of the α-receptor blocker tamsulosin, Damiano et al [19] and Wang et al [20•] found significantly decreased pain and urinary symptoms while improving quality of life compared with placebo controls.…”

Section: Oral Systemic Medicationsmentioning

confidence: 99%

Current Status of Ureteral Stent Technologies: Comfort and Antimicrobial Resistance

2010

View full text Add to dashboard Cite

show abstract

Effect of Tamsulosin in Preventing Ureteral Stent-Related Morbidity: A Prospective Study

Abstract: Our findings indicate that administration of tamsulosin has a positive effect on stent-related urinary symptoms and QoL. Further clinical research in this area is warranted to better define the role of alpha(1)-blockers in current clinical practice.

Cited by 94 publications

References 23 publications

Intraureteral lidocaine for ureteral stent symptoms post-ureteroscopy: A randomized, phase 2, placebo-controlled trial

Intraureteral lidocaine for ureteral stent symptoms post-ureteroscopy: A randomized, phase 2, placebo-controlled trial

Doxazosin oral intake therapy to relieve stent - related urinary symptoms and pain: a prospective, randomized, controlled study

Current Status of Ureteral Stent Technologies: Comfort and Antimicrobial Resistance

Contact Info

Product

Resources

About